Barclays analyst Gena Wang raised the firm’s price target on Alnylam (ALNY) to $460 from $329 and keeps an Overweight rating on the shares. The company’s Q2 report “hit every high note,” the analyst tells investors in a research note. The firm expects a continued “robust” Amvuttra launch with additional upside from Alnylam’s pipeline assets.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Alnylam Pharmaceuticals Reports Strong Q2 2025 Growth
- Alnylam Pharma’s Strong Financial Performance and Strategic Partnerships Justify Buy Rating
- Alnylam Pharma’s Strong Q2 2025 Performance and Raised Guidance Justify Buy Rating and Increased Price Target
- Alnylam Pharma’s Strong Financial Performance and Strategic Advancements Justify Buy Rating
- Alnylam raises FY25 revenue view to $2.65B-$2.8B from $2.05B-$2.25B